Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,626 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Eshmuminov D, Aminjonov B, Palm RF, Malleo G, Schmocker RK, Abdallah R, Yoo C, Shaib WL, Schneider MA, Rangelova E, Choi YJ, Kim H, Rose JB, Patel S, Wilson GC, Maloney S, Timmermann L, Sahora K, Rössler F, Lopez-Lopez V, Boyer E, Maggino L, Malinka T, Park JY, Katz MHG, Prakash L, Ahmad SA, Helton S, Jang JY, Hoffe SE, Salvia R, Taieb J, He J, Clavien PA, Held U, Lehmann K. Eshmuminov D, et al. Among authors: yoo c. Ann Surg Oncol. 2023 Jul;30(7):4417-4428. doi: 10.1245/s10434-023-13353-2. Epub 2023 Apr 5. Ann Surg Oncol. 2023. PMID: 37020094 Free PMC article. Review.
Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer.
Lee W, Park Y, Kwon JW, Jun E, Song KB, Lee JH, Hwang DW, Yoo C, Kim KP, Jeong JH, Chang HM, Ryoo BY, Park SY, Kim SC. Lee W, et al. Among authors: yoo c. J Clin Med. 2020 May 14;9(5):1477. doi: 10.3390/jcm9051477. J Clin Med. 2020. PMID: 32423123 Free PMC article.
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials.
Ledenko M, Antwi SO, Arima S, Driscoll J, Furuse J, Klümpen HJ, Larsen FO, Lau DK, Maderer A, Markussen A, Moehler M, Nooijen LE, Shaib WL, Tebbutt NC, André T, Ueno M, Woodford R, Yoo C, Zalupski MM, Patel T. Ledenko M, et al. Among authors: yoo c. Front Oncol. 2022 Aug 11;12:963753. doi: 10.3389/fonc.2022.963753. eCollection 2022. Front Oncol. 2022. PMID: 36033540 Free PMC article. No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 37067744
Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection.
Lim DH, Yoon H, Kim KP, Ryoo BY, Lee SS, Park DH, Song TJ, Hwang DW, Lee JH, Song KB, Kim SC, Hong SM, Hyung J, Yoo C. Lim DH, et al. Among authors: yoo c. Cancer Res Treat. 2023 Oct;55(4):1313-1320. doi: 10.4143/crt.2023.452. Epub 2023 May 4. Cancer Res Treat. 2023. PMID: 37139665 Free PMC article.
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma.
Yoon H, Shin Y, Ryoo BY, Jeong H, Park I, Seo DW, Lee SS, Park DH, Song TJ, Oh D, Hwang DW, Lee JH, Song KB, Park Y, Kwak BJ, Hong SM, Park JH, Kim SC, Kim KP, Yoo C. Yoon H, et al. Among authors: yoo c. Pancreatology. 2024 May;24(3):424-430. doi: 10.1016/j.pan.2024.02.004. Epub 2024 Feb 19. Pancreatology. 2024. PMID: 38395676
1,626 results